Top Vivus shareholder says proxy firm ISS backs three of nine board nominees(Reuters) - Vivus Inc's largest shareholder, First Manhattan Co, said on Friday proxy advisory firm Institutional Shareholder Services recommended three of the nine directors the shareholder had proposed for nomination to the drugmaker's board. Another advisory firm, Egan Jones, has backed all the nominees, while a third one, Glass Lewis, called Vivus's plan to launch diet drug Qsymia without a commercial partner "ill-advised", First Manhattan said in a statement. Qsymia's lackluster sales have been the main point of criticism by First Manhattan, which owns about 9.9 percent of the Vivus. ...
Source: Top Vivus shareholder says proxy firm ISS backs three of nine board nominees (http://news.yahoo.com/top-vivus-shareholder-says-proxy-firm-iss-backs-111642551.html)